Home / Health / New life-changing CF medication now covered in SK
New life-changing CF medication now covered in SK
5 Aug
Summary
- Alyftrek, a new cystic fibrosis medication, is now covered in Saskatchewan.
- The drug is available for patients aged six and older meeting medical criteria.
- Over 95 percent of Saskatchewan patients are candidates for this therapy.
Cystic fibrosis patients in Saskatchewan now have access to Alyftrek, a significant new medication that began provincial coverage on August 1, 2026. This drug is available to individuals aged six and older who meet established medical criteria.
Cystic fibrosis, a genetic disorder with no cure, impacts lung and digestive health. While over 4,500 Canadians live with CF, nearly 150 are in Saskatchewan. Alyftrek targets specific mutations, with over 95 percent of Saskatchewan patients being suitable candidates.
The province already funds other CF treatments like Trikafta, Orkambi, and Kalydeco. However, Alyftrek offers a crucial alternative for patients who cannot tolerate existing medications or have specific genetic mutations, potentially improving their treatment and overall quality of life.
